retatrutide and kidney function Comparison of the effects of Liraglutide, Tirzepatide, on diabetic disease in db/db mice | Endocrine Obesity and the kidney: mechanistic

Higher levels are associated with: Type 2 diabetes Fatty liver disease Elevated cholesterol High blood pressure Cardiovascular disease Sleep apnoea This is why many doctors now pay close attention to waist circumference, metabolic markers, and body composition rather than focusing only on total body weight

Because it affects three signaling pathways simultaneously, it enables investigation of receptor cross-talk and synergistic mechanisms that were difficult to study with single or dual-target compounds

fields Lilly, Novo (via the UBT-251 license and an internal NNC program), D&D Pharmatech (DD-03 / DD-15, both linked to Metsera and therefore now Pfizer after the 2025 acquisition), Protagonist, Cascade, and Rani

Tirzepatide is a dual agonist targeting GLP-1R and GIPR Retatrutide adds GCGR activation as a third receptor target

For the 2.4mg maintenance dose, you would need 240 units, which equals 2.4mL and definitely requires a larger syringe or multiple injections

Retatrutide is described in the literature as an investigational triple-hormone receptor agonist with activity across all three pathways